Christopher Benecchi - 11 Feb 2022 Form 4 Insider Report for Sage Therapeutics, Inc. (SAGE)

Role
Chief Commercial Officer
Signature
/s/ Jennifer Fitzpatrick, as Attorney-in-Fact for Christopher Benecchi
Issuer symbol
SAGE
Transactions as of
11 Feb 2022
Transactions value $
$0
Form type
4
Filing time
15 Feb 2022, 15:43:20 UTC
Previous filing
04 Oct 2021
Next filing
21 Jun 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SAGE Stock Option (Right to Buy) Award $0 +11.4K $0.00 11.4K 11 Feb 2022 Common Stock 11.4K $43.04 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The securities awarded on February 11, 2022 were in the form of stock options issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. Options to purchase 2,850 shares of common stock shall vest on the one year anniversary of February 11, 2022, with 8,550 shares vesting in 36 equal monthly installments thereafter.